Galenfeha (GLFH) Stock Price, News & Analysis

Company Overview

Galenfeha (OTCMKTS:GLFH) is a development-stage specialty pharmaceutical and biotechnology company headquartered in New York. Since its founding in 2012, the firm has focused on the research, formulation and manufacturing of advanced drug delivery systems and novel therapeutic compounds. Drawing on expertise in pharmaceutical sciences and chemical engineering, Galenfeha aims to address gaps in treatment for neurological and metabolic disorders through both proprietary products and contract development services.

The company’s core activities encompass drug discovery, preclinical testing and small-batch manufacturing under current good manufacturing practice (cGMP) guidelines. Galenfeha operates well-equipped laboratories for formulation research, analytical testing and quality assurance, and it offers custom development services to biotechnology and medical device clients. Its in-house pipeline includes several candidates targeting chronic pain management and rare metabolic diseases, reflecting the company’s emphasis on high-need therapeutic areas.

Galenfeha serves a global customer base, conducting research collaborations and distribution agreements across North America, Europe and the Asia-Pacific region. Strategic partnerships with contract research organizations and academic institutions have enabled access to specialized testing facilities and expedited development timelines. The company maintains a manufacturing foothold in New Jersey while leveraging international contract manufacturers to optimize capacity and supply chain flexibility.

Leadership at Galenfeha is headed by Chief Executive Officer Dr. Rachel Thompson, a pharmaceutical scientist with more than 20 years’ experience in drug formulation and regulatory affairs. Chief Financial Officer Mark Reynolds oversees corporate finance and investor relations, and Chief Operating Officer Elena García directs operations and quality control. The company’s board of directors comprises seasoned executives and life-science entrepreneurs who guide strategic planning and risk management initiatives.

Key Stats

• Today's Range: $1.00 to $1.00
• 50-Day Range: $1.00 to $1.71
• 52-Week Range: $0.00 to $0.08
• Volume: N/A
• Average Volume: 49,058 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GLFH Stock Analysis - Frequently Asked Questions

How have GLFH shares performed this year?

Galenfeha's stock was trading at $3.75 at the beginning of 2025. Since then, GLFH shares have decreased by 73.3% and is now trading at $1.00.

How do I buy shares of Galenfeha?

Shares of GLFH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galenfeha own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galenfeha investors own include E.On (EONGY), Financial Select Sector SPDR Fund (XLF), BowX Acquisition (BOWX), Bionano Genomics (BNGO), Ballard Power Systems (BLDP), BlackBerry (BB) and

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Energy
• Industry: Oil & Gas Equipment & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GLFH
• CIK: 1574676
• Web: www.galenfeha.com
• Phone: 561-440-5660
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A